Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.15
-0.06-1.87%
al cierre: -
$3.20
0.051.58%
After hour: 7:40 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Rocket Pharmaceuticals Inc ha un obiettivo di prezzo di consenso pari a $23.71, stabilito in base alle ultime valutazioni degli analisti di 20. Le ultime 3 valutazioni degli analisti sono state rilasciate da Leerink Partners, B of A Securities y Chardan Capital il octubre 3, 2025, agosto 20, 2025 y agosto 20, 2025. Con un obiettivo di prezzo medio di $9.33 tra le Leerink Partners, B of A Securities y Chardan Capital, c'è un implicito 191.68% upside per Rocket Pharmaceuticals Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Leerink Partners
B of A Securities
Chardan Capital
Cantor Fitzgerald
Canaccord Genuity
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Rocket Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/03/2025 | 118.76% | Leerink Partners | $9 → $7 | Maintains | Market Perform | |||
08/20/2025 | 212.52% | B of A Securities | $4 → $10 | Upgrade | Neutral → Buy | |||
08/20/2025 | 243.77% | Chardan Capital | $11 → $11 | Maintains | Buy | |||
08/11/2025 | 243.77% | Chardan Capital | $12 → $11 | Maintains | Buy | |||
08/08/2025 | 150.02% | Cantor Fitzgerald | $10 → $8 | Maintains | Overweight | |||
07/25/2025 | 212.52% | Canaccord Genuity | $11 → $10 | Maintains | Buy | |||
07/25/2025 | 25.01% | B of A Securities | $9 → $4 | Downgrade | Buy → Neutral | |||
07/24/2025 | 275.02% | Chardan Capital | $17 → $12 | Maintains | Buy | |||
07/24/2025 | — | Needham | — | Maintains | Hold | |||
06/17/2025 | 56.26% | UBS | $12 → $5 | Maintains | Buy | |||
06/03/2025 | 243.77% | Canaccord Genuity | $34 → $11 | Maintains | Buy | |||
05/28/2025 | 181.27% | B of A Securities | $32 → $9 | Maintains | Buy | |||
05/28/2025 | 150.02% | BMO Capital | $30 → $8 | Maintains | Outperform | |||
05/28/2025 | 493.79% | Scotiabank | $51 → $19 | Maintains | Sector Outperform | |||
05/28/2025 | 150.02% | Leerink Partners | $37 → $8 | Downgrade | Outperform → Market Perform | |||
05/28/2025 | 431.28% | Chardan Capital | $46 → $17 | Maintains | Buy | |||
05/28/2025 | -21.87% | Jefferies | $29 → $2.5 | Downgrade | Buy → Hold | |||
05/27/2025 | 900.06% | B of A Securities | $34 → $32 | Maintains | Buy | |||
05/27/2025 | 1212.58% | Needham | $42 → $42 | Downgrade | Buy → Hold | |||
05/16/2025 | 837.56% | Cantor Fitzgerald | $20 → $30 | Maintains | Overweight | |||
05/16/2025 | 900.06% | Wedbush | $32 → $32 | Reiterates | Outperform → Outperform | |||
05/16/2025 | 1337.59% | Chardan Capital | $45 → $46 | Maintains | Buy | |||
05/12/2025 | 1493.85% | Scotiabank | $52 → $51 | Maintains | Sector Outperform | |||
05/12/2025 | 962.57% | Canaccord Genuity | $36 → $34 | Maintains | Buy | |||
05/09/2025 | 1306.34% | Chardan Capital | $54 → $45 | Maintains | Buy | |||
05/09/2025 | 1275.09% | JP Morgan | $45 → $44 | Maintains | Overweight | |||
05/09/2025 | 306.28% | Goldman Sachs | $15 → $13 | Maintains | Neutral | |||
04/09/2025 | 1212.58% | Needham | $42 → $42 | Reiterates | Buy → Buy | |||
03/12/2025 | 1462.6% | BMO Capital | → $50 | Initiates | → Outperform | |||
03/03/2025 | 1525.1% | Scotiabank | $51 → $52 | Maintains | Sector Outperform | |||
03/03/2025 | 368.78% | Goldman Sachs | $29 → $15 | Maintains | Neutral | |||
03/03/2025 | 1025.07% | Canaccord Genuity | $39 → $36 | Maintains | Buy | |||
02/28/2025 | 1462.6% | Cantor Fitzgerald | $65 → $50 | Maintains | Overweight | |||
02/28/2025 | 1587.61% | Chardan Capital | $62 → $54 | Maintains | Buy | |||
02/28/2025 | 1212.58% | Needham | $52 → $42 | Maintains | Buy | |||
12/18/2024 | 806.31% | Jefferies | → $29 | Initiates | → Buy | |||
12/11/2024 | 1150.08% | Leerink Partners | $44 → $40 | Maintains | Outperform | |||
11/19/2024 | 1118.83% | Canaccord Genuity | $39 → $39 | Maintains | Buy | |||
11/19/2024 | 1275.09% | Leerink Partners | $46 → $44 | Maintains | Outperform | |||
11/19/2024 | 1931.38% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
11/19/2024 | 1525.1% | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
11/18/2024 | 1837.62% | Chardan Capital | $62 → $62 | Maintains | Buy | |||
11/11/2024 | 1837.62% | Chardan Capital | $62 → $62 | Maintains | Buy | |||
11/08/2024 | 1525.1% | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
10/16/2024 | 1462.6% | Scotiabank | → $50 | Initiates | → Sector Outperform | |||
09/30/2024 | 1087.57% | Canaccord Genuity | $38 → $38 | Maintains | Buy | |||
09/17/2024 | 1525.1% | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
08/06/2024 | 1587.61% | JP Morgan | $50 → $54 | Maintains | Overweight | |||
08/06/2024 | 1931.38% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
08/06/2024 | 1837.62% | Chardan Capital | $62 → $62 | Maintains | Buy | |||
08/06/2024 | 1525.1% | Needham | $52 → $52 | Reiterates | Buy → Buy | |||
07/03/2024 | 1150.08% | Canaccord Genuity | $49 → $40 | Maintains | Buy | |||
06/28/2024 | 1837.62% | Chardan Capital | $62 → $62 | Maintains | Buy | |||
06/28/2024 | 1525.1% | Needham | $53 → $52 | Maintains | Buy | |||
05/07/2024 | 1556.35% | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
04/10/2024 | 1556.35% | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
04/02/2024 | 1118.83% | Goldman Sachs | → $39 | Initiates | → Neutral | |||
03/01/2024 | 1587.61% | UBS | $56 → $54 | Maintains | Buy | |||
02/27/2024 | 1462.6% | JP Morgan | $55 → $50 | Maintains | Overweight | |||
02/27/2024 | 1931.38% | Cantor Fitzgerald | $65 → $65 | Maintains | Overweight | |||
02/13/2024 | 1556.35% | Needham | $53 → $53 | Reiterates | Buy → Buy | |||
01/31/2024 | 1931.38% | Cantor Fitzgerald | $65 → $65 | Reiterates | Overweight → Overweight | |||
11/07/2023 | 1556.35% | Needham | → $53 | Reiterates | Buy → Buy | |||
10/24/2023 | 1931.38% | Cantor Fitzgerald | → $65 | Initiates | → Overweight | |||
09/13/2023 | 1400.09% | Stifel | → $48 | Reiterates | Buy → Buy | |||
09/13/2023 | 1556.35% | Needham | $60 → $53 | Maintains | Buy | |||
08/11/2023 | 1368.84% | Canaccord Genuity | $49 → $47 | Maintains | Buy | |||
08/11/2023 | 1806.37% | Chardan Capital | → $61 | Reiterates | Buy → Buy | |||
08/10/2023 | 1775.12% | Needham | → $60 | Reiterates | Buy → Buy | |||
08/10/2023 | 1400.09% | Stifel | $53 → $48 | Maintains | Buy | |||
05/23/2023 | 1775.12% | Needham | → $60 | Reiterates | Buy → Buy | |||
05/08/2023 | 1806.37% | Chardan Capital | $63 → $61 | Maintains | Buy | |||
05/05/2023 | 993.82% | Raymond James | $33 → $35 | Maintains | Outperform | |||
05/05/2023 | 1775.12% | Needham | → $60 | Reiterates | → Buy | |||
04/19/2023 | 1775.12% | Needham | → $60 | Reiterates | → Buy | |||
03/01/2023 | 1868.87% | Chardan Capital | $65 → $63 | Reiterates | → Buy | |||
02/28/2023 | 1775.12% | Needham | → $60 | Reiterates | → Buy | |||
02/01/2023 | 1306.34% | Morgan Stanley | → $45 | Initiates | → Overweight | |||
01/23/2023 | 1431.35% | SVB Leerink | $50 → $49 | Maintains | Outperform | |||
12/23/2022 | 993.82% | B of A Securities | $38 → $35 | Maintains | Buy | |||
12/22/2022 | 1462.6% | SVB Leerink | $54 → $50 | Maintains | Outperform | |||
12/06/2022 | 1587.61% | SVB Leerink | $56 → $54 | Maintains | Outperform | |||
11/08/2022 | 1556.35% | Canaccord Genuity | → $53 | Initiates | → Buy | |||
11/07/2022 | 931.31% | Raymond James | $34 → $33 | Maintains | Outperform | |||
11/04/2022 | 1775.12% | Needham | $62 → $60 | Maintains | Buy | |||
11/01/2022 | 993.82% | BTIG | → $35 | Initiates | → Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Rocket Pharmaceuticals (RCKT)?
El último precio objetivo de Rocket Pharmaceuticals (NASDAQ:RCKT) fue comunicado por Leerink Partners el octubre 3, 2025. La firma de analistas fijó un precio objetivo para $7.00 que espera RCKT a rise dentro de 12 meses (un posible 118.76% upside). 45 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Rocket Pharmaceuticals (RCKT)?
La última calificación de analistas para Rocket Pharmaceuticals (NASDAQ:RCKT) fue proporcionada por Leerink Partners, y Rocket Pharmaceuticals mantuvo su market perform calificación.
¿Cuándo se produjo la última revisión al alza de Rocket Pharmaceuticals (RCKT)?
La última revisión al alza de Rocket Pharmaceuticals Inc se produjo en agosto 20, 2025, cuando B of A Securities elevó su precio objetivo a $10. B of A Securities anteriormente tenía a neutral para Rocket Pharmaceuticals Inc.
¿Cuándo fue la última revisión a la baja de Rocket Pharmaceuticals (RCKT)?
La última revisión a la baja de Rocket Pharmaceuticals Inc se produjo en julio 25, 2025, cuando B of A Securities cambió su precio objetivo de $9 a $4 para Rocket Pharmaceuticals Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Rocket Pharmaceuticals (RCKT)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Rocket Pharmaceuticals, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Rocket Pharmaceuticals se registró el octubre 3, 2025, por lo que la próxima calificación estará disponible en torno al octubre 3, 2026.
¿Es correcta la calificación de los analistas sobre Rocket Pharmaceuticals (RCKT)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Rocket Pharmaceuticals (RCKT) fue un mantuvo con un precio objetivo de $9.00 a $7.00. El precio actual al que cotiza Rocket Pharmaceuticals (RCKT) es de $3.20, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.